Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Kavanagh

Showing results (101-110 of 193) with videos related to

Pageof 20
Sort By:
Kidney International Reports|July 13, 2023
Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic SyndromeDavid Kavanagh, Larry A Greenbaum, Arvind Bagga, et al.
Kidney International Reports|January 16, 2026
Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative GlomerulonephritisDavid Kavanagh, Gema Ariceta, Marina Vivarelli, et al.
Renal Failure|June 15, 2010
Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1)Diogo Bento, Joana Mapril, Carla Rocha, et al.
Addictive Behaviors|December 27, 2011
Reasons for substance use among people with mental disordersLouise K Thornton, Amanda L Baker, Terry J Lewin, et al.
Kidney International Reports|October 11, 2022
Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G TrialAndrew S Bomback, David Kavanagh, Marina Vivarelli, et al.
Kidney International Reports|February 5, 2024
Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 StudyMarina Vivarelli, Andrew S Bomback, Matthias Meier, et al.
The Journal of Biological Chemistry|February 7, 2008
Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variationsHenry G Hocking, Andrew P Herbert, David Kavanagh, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 10, 2025
Late Onset Thrombotic Microangiopathy in Kidney Transplants; Poor Outcome Despite Eculizumab TreatmentEmily K Glover, Emma K Montgomery, Edwin K S Wong, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2008
A new map of glycosaminoglycan and C3b binding sites on factor HChristoph Q Schmidt, Andrew P Herbert, David Kavanagh, et al.
Kidney International Reports|June 25, 2021
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in AdultsThomas Barbour, Marie Scully, Gema Ariceta, et al.
Pageof 20

Showing results (101-110 of 193) with videos related to

Sort By:
Pageof 20
Kidney International Reports|July 13, 2023
Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic SyndromeDavid Kavanagh, Larry A Greenbaum, Arvind Bagga, et al.
Kidney International Reports|January 16, 2026
Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative GlomerulonephritisDavid Kavanagh, Gema Ariceta, Marina Vivarelli, et al.
Renal Failure|June 15, 2010
Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1)Diogo Bento, Joana Mapril, Carla Rocha, et al.
Addictive Behaviors|December 27, 2011
Reasons for substance use among people with mental disordersLouise K Thornton, Amanda L Baker, Terry J Lewin, et al.
Kidney International Reports|October 11, 2022
Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G TrialAndrew S Bomback, David Kavanagh, Marina Vivarelli, et al.
Kidney International Reports|February 5, 2024
Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 StudyMarina Vivarelli, Andrew S Bomback, Matthias Meier, et al.
The Journal of Biological Chemistry|February 7, 2008
Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variationsHenry G Hocking, Andrew P Herbert, David Kavanagh, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 10, 2025
Late Onset Thrombotic Microangiopathy in Kidney Transplants; Poor Outcome Despite Eculizumab TreatmentEmily K Glover, Emma K Montgomery, Edwin K S Wong, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2008
A new map of glycosaminoglycan and C3b binding sites on factor HChristoph Q Schmidt, Andrew P Herbert, David Kavanagh, et al.
Kidney International Reports|June 25, 2021
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in AdultsThomas Barbour, Marie Scully, Gema Ariceta, et al.
Pageof 20